EWP
FLGT icon

Engrave Wealth Partners’s Fulgent Genetics FLGT Stock Holding History

Engrave Wealth Partners’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$3K – 190
2020
Q2 		$3K Buy
+200
New +$3.06K ﹤0.01% 358

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJT
Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Engrave Wealth Partners's FLGT Position: Q3 2020 in Review

Engrave Wealth Partners sold out of Fulgent Genetics (FLGT) in Q3 2020, closing a stake of 200 shares — an estimated $3K sold.

Engrave Wealth Partners first reported a position in FLGT in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 126 funds tracked by Wall St. Rank hold FLGT as of Q3 2020.

  • Engrave Wealth Partners reported no remaining Fulgent Genetics position as of Q3 2020 after selling out during the quarter.
  • Engrave Wealth Partners sold 200 Fulgent Genetics shares in Q3 2020, an estimated $3K.
  • Engrave Wealth Partners first reported a position in Fulgent Genetics in Q2 2020 and held it in 1 quarter.
  • Engrave Wealth Partners's Fulgent Genetics position peaked at $3K in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2020.

Based on Engrave Wealth Partners's 13F filing for Q3 2020, filed 8 Oct 2020.